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a b s t r a c t
Background: There is limited information on use of laser in complex percutaneous coronary interventions (PCI).
We examined the impact of laser on the outcomes of balloon uncrossable and balloon undilatable chronic total
occlusion (CTO) PCI.
Methods: We reviewed baseline clinical and angiographic characteristics and procedural outcomes of 4845 CTO
PCIs performed between 2012 and 2020 at 32 centers.
Results: Of the 4845 CTO lesions, 752 (15.5%) were balloon uncrossable (523 cases) or balloon undilatable (356
cases) and were included in this analysis. Mean patient age was 66.9 ± 10 years and 83% were men. Laser was
used in 20.3% of the lesions. Compared with cases in which laser was not used, laser was more commonly
used in longer length occlusions (33 [21, 50] vs. 25 [15, 40] mm, p = 0.0004) and in-stent restenotic lesions
(41% vs. 20%, p < 0.0001). Laser use was associated with higher technical (91.5% vs. 83.1%, p = 0.010) and procedural (88.9% vs. 81.6%, p = 0.033) success rates and similar incidence of major adverse cardiac events (3.92% vs.
3.51%, p = 0.805). Laser use was associated with longer procedural (169 [109, 231] vs. 130 [87, 199], p < 0.0001)
and ﬂuoroscopy time (64 [40, 94] vs. 50 [31, 81], p = 0.003).
Conclusions: In a contemporary, multicenter registry balloon uncrossable and balloon undilatable lesions represented 15.5% of all CTO PCIs. Laser was used in approximately one-ﬁfth of these cases and was associated with
high technical and procedural success and similar major complication rates.
© 2021 Elsevier B.V. All rights reserved.

1. Introduction
Laser is an important tool in complex percutaneous coronary intervention (PCI), even though there is limited information on real-world
use and outcomes. [1–3] We examined the impact of laser on the outcomes of PCI of balloon uncrossable and balloon undilatable chronic
total occlusions (CTO) (Supplementary Fig. 1). Balloon uncrossable
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lesions are deﬁned as lesions that cannot be crossed with a balloon
after successful guidewire crossing. Balloon uncrossable lesions are relatively common, representing 6.4% of the CTO lesions in a single center
study (laser was used in 18% of the lesions) [4] and 9% in a multicenter
CTO registry (laser was used in 8.7% of the lesions). [5] Balloon
undilatable lesions are lesions that do not expand despite highpressure balloon inﬂations; approximately 12% of the CTO lesions
were balloon undilatable in the same multicenter CTO registry. [6]
Laser can provide effective treatment for both lesion types. No
guidewire exchange is necessary when using laser for balloon uncrossable lesions. Laser can either cross such lesions or modify them enough
to facilitate subsequent balloon advancement. [7] Laser can also help expand balloon undilatable lesions, sometimes with simultaneous contrast administration when treating in-stent undilatable lesions. [1,8–10]
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2. Materials and methods
We analyzed the baseline clinical and angiographic characteristics
and procedural outcomes of 4845 CTO PCIs performed between 2012
and 2020 enrolled at 32 centers. Data collection was performed both
prospectively and retrospectively and was recorded in a dedicated online database (PROGRESS CTO: Prospective Global Registry for the
Study of Chronic Total Occlusion Intervention; Clinicaltrials.gov identiﬁer: NCT02061436). Study data were collected and managed using
REDCap (Research Electronic Data Capture) electronic data capture
tools hosted at Minneapolis Heart Institute Foundation. [11,12] The
study was approved by the institutional review board of each site.
Coronary CTOs were deﬁned as coronary lesions with Thrombolysis
in Myocardial Infarction (TIMI) grade 0 ﬂow of at least 3-month duration. Estimation of the duration of occlusion was clinical, based on the
ﬁrst onset of angina, prior history of myocardial infarction (MI) in the
target vessel territory, or comparison with a prior angiogram Calciﬁcation was assessed by angiography as mild (spots), moderate (involving
≤50% of the reference lesion diameter), or severe (involving >50% of the
reference lesion diameter). Moderate proximal vessel tortuosity was
deﬁned as the presence of at least 2 bends >70° or 1 bend >90° and severe tortuosity as 2 bends >90° or 1 bend >120° in the CTO vessel. A retrograde procedure was an attempt to cross the lesion through a
collateral vessel or bypass graft supplying the target vessel distal to
the lesion; otherwise, the intervention was classiﬁed as an antegradeonly procedure. Antegrade dissection/re-entry was deﬁned as
antegrade PCI during which a guidewire was intentionally introduced
into the subintimal space proximal to the lesion, or re-entry into the distal true lumen was attempted after intentional or inadvertent
subintimal guidewire crossing. Technical success was deﬁned as successful CTO revascularization with achievement of <30% residual diameter stenosis within the treated segment and restoration of TIMI grade 3
antegrade ﬂow. Procedural success was deﬁned as the achievement of
technical success without any in-hospital complications. In-hospital
major adverse cardiac event (MACE) included any of the following adverse events prior to hospital discharge: death, MI, recurrent symptoms
requiring urgent repeat target-vessel revascularization (TVR) with PCI
or coronary artery bypass graft (CABG) surgery, tamponade requiring
either pericardiocentesis or surgery, and stroke. MI was deﬁned using
the Third Universal Deﬁnition of Myocardial Infarction (type 4a MI).
[13] The Japanese CTO (J-CTO) score was calculated as described by
Morino et al., [14] the PROGRESS-CTO score as described by
Christopoulos et al. [15] The decision to use laser atherectomy and the
associated techniques was at the operators' discretion.
Categorical variables were expressed as percentages and were compared using Pearson's Chi-square test or Fisher's exact test. Continuous
variables were presented as mean ± standard deviation or median (interquartile range [IQR]) unless otherwise speciﬁed and were compared
using the student's t-test and one-way analysis of variance (ANOVA) for
normally distributed variables and the Wilcoxon rank-sum test, or the
Kruskal-Wallis test for non-parametric continuous variables, as appropriate. Logistic regression analysis was performed to identify clinical and
angiographic parameters associated with technical success. Variables
with p < 0.10 on univariate analysis (presence of proximal cap ambiguity,
in-stent restenosis, prior failed CTO PCI, presence of interventional
collaterals, use of laser) were included in a multivariate model. All
statistical analyses were performed using JMP, version 13.0 (SAS Institute). A P-value of <0.05 was considered statistically signiﬁcant.

Fig. 1. A. Temporal trends in number of laser cases in balloon uncrossable and undilatable
chronic total occlusions (CTOs).
B. Temporal trends in proportion of laser cases in balloon uncrossable and undilatable
chronic total occlusions (CTOs).

Laser was used in 153 CTO lesions (20.3%). The baseline clinical characteristics of the study patients are summarized in Table 1. Mean patient
age was 66.9 ± 10 years, 83% were men, 51% had diabetes mellitus and
42% had prior coronary artery bypass graft surgery. Patients in whom
laser was used were more likely to have diabetes than the patients who
did not undergo laser treatment (61% vs. 48%, p = 0.005). There was no
other difference in baseline clinical characteristics between the two
groups.
The angiographic characteristics and procedural strategies are summarized in Table 1. The most common target vessel was the right coronary artery (55%) followed by the left anterior descending (22%) and
left circumﬂex coronary artery (21%). The study lesions were complex:
moderate or severe calciﬁcation was present in 73%, mean Japan CTO
score was 2.79 ± 1.19, and mean PROGRESS CTO score was 1.36 ±
1.02. Compared with cases in which laser was not used, laser was
more commonly used in lesions with longer occlusion length (33 [21,
50] vs. 25 [15, 40] mm, p = 0.0004) and in-stent occlusions (41% vs.
20%, p < 0.0001).
Procedural characteristics and outcomes are listed in Table 2. The
overall technical and procedural success were 84.8% and 83.1%, respectively. The incidence of in-hospital MACE was 3.59%. Laser use was associated with higher technical (91.5% vs. 83.1%, p = 0.010) and procedural
(88.9% vs. 81.6%, p = 0.033) success rates (Fig. 2A) and similar incidence
of MACE (3.92% vs. 3.51%, p = 0.805, Fig. 2B). On multivariable analysis
laser was no longer associated with technical success (Supplementary
Fig. 2).
There was no difference in the components of MACE and other
complications between the two groups (Table 2). Laser use was
associated with longer procedural (169 [109, 231] vs. 130 [87, 199] min,
p < 0.0001) and ﬂuoroscopy (64 [40, 94] vs. 50 [31, 81] min, p = 0.003)
time but similar contrast volume (200 [141, 295] vs. 201 [150, 280] ml,
p = 0.567). Other techniques used in balloon uncrossable and undilatable

3. Results
Of the 4845 CTOs, 752 (15.5%) were balloon uncrossable (523 cases)
or balloon undilatable (356 cases) and were included in the present analysis (127 cases were both balloon uncrossable and undilatable). A gradual increase in laser use was observed from 2012 to 2019 (p < 0.0001,
Fig. 1; a decrease in 2020 was likely related to the COVID-19 outbreak).
2
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bonds), photothermal (tissue vaporization) and photokinetic (quick expansion and collapse of the vapor bubbles breaks down the plaque) [7].
Use of laser can facilitate complex PCI. [2,7]
Potential treatment strategies for balloon uncrossable lesions are use
of low proﬁle semi-compliant balloons with lubricous coating,
microcatheters, stronger guide catheter support, for example using
guide catheter extensions or anchoring techniques. Second line treatments include laser atherectomy, balloon assisted microdissection, and
rotational and orbital atherectomy. The third line strategy is subintimal
dissection and re-entry. Strategies for treating balloon undilatable lesions
include non-compliant balloons, ultrahigh pressure non-compliant balloons, cutting/scoring balloons, laser, rotational and orbital atherectomy
and intravascular lithotripsy. [9] Rotational atherectomy can facilitate
treatment of both balloon uncrossable and balloon undilatable lesions.
Aggressive burr advancement should be avoided in balloon uncrossable
lesions to reduce the risk of entrapment as only the distal part of the
burr is coated with diamond crystals. [17] Orbital atherectomy can also
treat balloon undilatable and balloon uncrossable lesions, but requires
slow crown advancement in contrast to the rapid “pecking” motion recommended for rotational atherectomy. In a recently published metaanalysis, except for lower ﬂuoroscopy time with orbital atherectomy, no
signiﬁcant differences were observed between orbital and rotational atherectomy in relation to procedural, periprocedural, and thirty day outcomes among patients with calciﬁed coronary lesions. [18] Laser is an
excellent treatment option for balloon uncrossable lesions as as it can be
advanced over any standard 0.014 in. guidewire, in contrast to orbital
and rotational atherectomy that require specialized guidewires. Multiple
passes may be required to cross the lesion. [19] Laser with simultaneous
contrast injection can be effective in treating in-stent balloon undilatable
lesions [2,8] and can sometimes be combined with brachytherapy to reduce the risk of recurrent restenosis. [20]
Ferdandez et al. examined laser use in 58 patients, 16 of whom had
balloon uncrossable CTOs (in two of these laser was combined with rotational atherectomy) with procedural success of 87.5% and 2% incidence of complications. In the same study laser alone was used in two
balloon undilatable CTO cases with 100% success rate and one case of
Ellis class I perforation. [21] Another study examining laser use in veterans undergoing PCI reported balloon uncrossable lesions to be the
most common indication for laser (43.8%) with 87.8% technical and
83.7% procedural success. The second most common indication was balloon undilatable lesions (40.8%) with 94.3% and 93.8%, technical and
procedural success rates, respectively. [2] The LEONARDO study (Early
outcome of high energy Laser (Excimer) facilitated coronary angioplasty ON hARD and complex calciﬁed and balloOn-resistant coronary
lesions) enrolled 80 patients with 100 lesions and reported 93.7% success rate (30 of 32) without any complications. [22] Finally, the
ELLEMENT (Excimer Laser LEsion modiﬁcation to expand nondilatable stents) study examined laser at high energy with simultaneous
contrast injection within under-expanded stents with 96.4% success
and 7.1% incidence of periprocedural myocardial infarction. [23] Laser
can be used over any standard 0.014 in. guidewire, which makes it easier to apply than other ablative devices that require use of a dedicated
guidewire, such as rotational and orbital atherectomy.

Table 1
Baseline clinical, angiographic and technical characteristics of study patients and
procedures.
Variable

Laser used
(n = 153)

(n = 599)

Age (years)a
Men
BMI (kg/m2)a
Diabetes Mellitus
Hypertension
Dyslipidemia
Smoking (current)
LVEF (%)a
Family History of CAD
Congestive Heart Failure
Prior Myocardial Infarction
Prior CABG
Prior CVD
Prior PVD
Baseline creatinine (mg/dL)b

65.7 ± 9
84%
30.6 ± 7
61%
92%
96%
19%
49 ± 14
36%
31%
54%
44%
12%
18%
1.0 (0.9,
1.3)

67.2 ± 10
82%
29.8 ± 6
48%
93%
93%
22%
49 ± 13
38%
33%
46%
41%
11%
16%
1.0 (0.9,
1.2)

0.077
0.524
0.167
0.005
0.569
0.223
0.457
0.692
0.722
0.618
0.130
0.616
0.861
0.457
0.349

56%
21%
21%
1%
1.4%

54%
22%
21%
0.5%
2.1%

0.968

63%
20%
11%
6%

61%
18%
10%
11%

0.329

87%
11%
3%
2.89 ± 1.10
1.27 ± 1.02
71%
35%

87%
10%
3%
2.77 ± 1.21
1.38 ± 1.02
74%
40%

0.993

26%
41%
28%
50%
49%
3.0 (2.5,
3.0)
33 (21, 50)
2.52 ± 1.10

35%
20%
24%
55%
55%
3.0 (2.5,
3.0)
25 (15, 40)
2.42 ± 1.13

Angiographic and technical characteristics
CTO Target Vessel
▪ RCA
▪ LAD
▪ LCX
▪ LM
▪ Other
Successful Crossing Strategy
▪ Antegrade wiring
▪ Retrograde
▪ ADR
▪ None
First Crossing Strategy
▪ Antegrade wiring
▪ Retrograde
▪ ADR
J-CTO scorea
Progress CTO scorea
Calciﬁcation (moderate/severe)
Proximal vessel tortuosity
(moderate/severe)
Proximal cap ambiguity
In-stent restenosis
Prior failure to open CTO
Side branch at the proximal cap
Blunt/no stump, %
Vessel diameter (mm)b
Occlusion length (mm)b
Number of stents useda

Laser not
used

P value

0.251
0.238
0.498
0.193
0.052
<0.001
0.252
0.221
0.178
0.169
0.0004
0.344

(BMI: Body Mass Index, LVEF: Left Ventricular Ejection Fraction; CAD: Coronary Artery
Disease; CABG: Coronary Artery Bypass Grafting; CVD: Cerebrovascular Disease; PVD: Peripheral Vascular Disease; CTO: chronic total occlusion; RCA: right coronary artery, LAD:
left descending coronary artery, LCX: left circumﬂex coronary artery; LM: left main coronary artery; ADR: antegrade dissection and re-entry; J-CTO: Japan CTO score; PROGRESS-CTO score: Prospective Global Registry for the Study of Chronic Total Occlusion
Intervention score)
a
Mean ± standard deviation.
b
Median (interquartile ranges).

CTO lesions are summarized in Supplementary Table 3: rotational atherectomy and grenadoplasty were the most commonly used techniques.

5. Study limitations
Limitations of our study are the observational design, the lack of clinical event adjudication, and performance of all procedures at highvolume, experienced PCI centers, limiting the generalizability of our
ﬁndings to centers with limited CTO PCI experience.

4. Discussion
The main ﬁnding of our study is that use of laser in balloon uncrossable and balloon undilatable CTO lesions was associated with high technical and procedural success and similar major complication rates.
Laser was ﬁrst approved by the U.S. Food and Drug Administration
for PCI in 1992 [16] The term laser is obtained from the acronym
“Light Ampliﬁcation by Stimulated Emission of Radiation” [7] Laser ablates tissue in three ways: photochemical (fracture of molecular

6. Conclusion
Laser can facilitate treatment of balloon uncrossable and balloon
undilatable CTOs with high technical and procedural success and low
complication rates. Given the observational design of our study, the
3
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Fig. 2. A. Technical, procedural success and major cardiac events (MACE) among balloon uncrossable and undilatable procedures, classiﬁed according to laser use.
B. Procedural complications among study procedures, classiﬁed according to laser use in balloon uncrossable and undilatable procedures.
(MACE: major cardiac adverse events)

Table 2
Procedural characteristics and outcomes of study patients.
Variable

Technical Success
Procedural Success
Procedural time (min)b
Fluoroscopy time (min)b
Air kerma radiation dose (Gray)b
Contrast volumeb
MACE
Death
Acute Q wave MI
Acute MI
Re-PCI
Stroke
Emergency CABG
Pericardiocentesis
Perforation
Tamponade
Dissection/Thrombus of Donor
Artery

Laser used

Laser not used

(n = 153)

(n = 599)

91.5%
88.9%
169 (109, 231)
64 (40, 94)
2.50 (1.76,
4.20)
200 (141, 295)
3.92%
1.31%
0%
1.31%
0.00%
0.00%
0.00%
1.31%
4.58%
1.31%
1.31%

83.1%
81.6%
130 (87, 199)
50 (31, 81)
2.45 (1.37,
3.98)
201 (150, 280)
3.51%
0.50%
0%
0.83%
0.17%
0.17%
0.33%
2.34%
8.18%
1.67%
0.83%
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P value

0.010
0.033
<0.001
0.003
0.455
0.567
0.805
0.273
–
0.587
0.613
0.613
0.474
0.431
0.130
0.750
0.587

(MACE: major cardiac adverse events; MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: Coronary Artery Bypass Grafting)
b
Median (interquartile ranges).

results should be considered hypothesis-generating, highlighting the
need for further research.
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